Acaluxen is identified on this website as a product containing 100 mg of acalabrutinib. The exact manufacturer, dosage form, authorization pathway and commercial product history require product-specific verification.
Acalabrutinib is a targeted anticancer medicine belonging to the BTK inhibitor class. BTK is a signaling enzyme involved in B-cell receptor pathways, which are important for B-cell activation and survival.
Product identity
| Attribute | Information |
|---|---|
| Product | Acaluxen |
| Generic name | Acalabrutinib |
| Stated strength | 100 mg |
| Drug class | BTK inhibitor |
| Therapeutic category | Antineoplastic |
| Route | Oral, subject to product verification |
| Reference brand | CALQUENCE |
| Acaluxen manufacturer | Everest Pharmaceuticals Ltd. |
Current U.S. CALQUENCE capsule labeling identifies a 100 mg capsule. The current U.S. label was revised in February 2026.
Acalabrutinib and CALQUENCE
CALQUENCE is the established branded acalabrutinib medicine in the U.S. and EU. Acalabrutinib was originally developed by Acerta Pharma, with AstraZeneca acquiring a majority interest in Acerta in 2016.
Acaluxen should not be described as CALQUENCE or as being manufactured by AstraZeneca unless product documentation establishes that relationship.
Why 100 mg matters
The 100 mg designation identifies the amount of acalabrutinib contained in the dosage unit. It does not by itself determine the correct treatment regimen for an individual patient.
The current U.S. labeling generally recommends 100 mg approximately every 12 hours for the approved CALQUENCE indications, subject to indication, drug interactions, organ function and toxicity-related modifications.
Product-specific limitations
Information about Acaluxen’s:
- manufacturer,
- marketing authorization holder,
- manufacturing site,
- packaging,
- country-specific approval,
- batch-verification system, and
- supply chain